Harrington Investments INC Buys 211 Shares of Amgen Inc. (NASDAQ:AMGN)

Harrington Investments INC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,206 shares of the medical research company’s stock after buying an additional 211 shares during the quarter. Amgen makes up 2.1% of Harrington Investments INC’s holdings, making the stock its 13th biggest holding. Harrington Investments INC’s holdings in Amgen were worth $2,943,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. FMR LLC grew its stake in shares of Amgen by 24.9% in the second quarter. FMR LLC now owns 8,911,384 shares of the medical research company’s stock worth $2,168,140,000 after purchasing an additional 1,774,223 shares during the last quarter. Vanguard Group Inc. grew its position in Amgen by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 47,459,511 shares of the medical research company’s stock valued at $10,697,373,000 after purchasing an additional 1,310,894 shares during the period. Renaissance Technologies LLC boosted its stake in Amgen by 279.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,439,745 shares of the medical research company’s stock valued at $350,290,000 after purchasing an additional 1,060,200 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Amgen by 164.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,337,970 shares of the medical research company’s stock valued at $323,548,000 after buying an additional 832,885 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in Amgen by 84.5% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,201,655 shares of the medical research company’s stock worth $270,853,000 after acquiring an additional 550,439 shares during the last quarter. Institutional investors own 75.53% of the company’s stock.

Amgen Trading Down 2.0 %

Shares of AMGN traded down $4.78 during midday trading on Friday, hitting $229.79. The stock had a trading volume of 7,817,122 shares, compared to its average volume of 2,275,721. The firm has a market cap of $122.70 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 1.89 and a beta of 0.65. Amgen Inc. has a 1 year low of $223.30 and a 1 year high of $296.67. The stock’s 50 day moving average is $245.91 and its 200 day moving average is $254.81. The company has a debt-to-equity ratio of 10.20, a current ratio of 1.41 and a quick ratio of 1.10.

Amgen (NASDAQ:AMGN – Get Rating) last issued its earnings results on Tuesday, February 7th. The medical research company reported $4.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.05. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The company had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.77 billion. During the same period in the prior year, the business earned $4.36 EPS. The firm’s quarterly revenue was down .1% on a year-over-year basis. As a group, analysts forecast that Amgen Inc. will post 17.72 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Thursday, May 18th will be paid a $2.13 dividend. This represents a $8.52 dividend on an annualized basis and a yield of 3.71%. The ex-dividend date of this dividend is Wednesday, May 17th. Amgen’s dividend payout ratio (DPR) is presently 70.36%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on AMGN shares. Wells Fargo & Company raised shares of Amgen from an “equal weight” rating to an “overweight” rating and reduced their price objective for the stock from $275.00 to $265.00 in a research report on Monday, March 13th. BMO Capital Markets dropped their price target on shares of Amgen from $276.00 to $253.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 1st. SVB Securities cut their price target on shares of Amgen from $282.00 to $267.00 in a report on Thursday, February 2nd. SVB Leerink cut their price target on shares of Amgen from $282.00 to $267.00 and set a “market perform” rating for the company in a report on Thursday, February 2nd. Finally, Argus lowered their price objective on shares of Amgen from $300.00 to $270.00 in a research report on Monday, February 6th. Four research analysts have rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $251.44.

About Amgen

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.